Galera Therapeutics, Inc. is a biopharmaceutical company that, following the October 2025 sale of its SOD mimetics assets to Biossil, Inc., has shifted focus to developing a pan-nitric oxide synthase (NOS) inhibitor, tilarginine (L-NMMA), for treating metaplastic breast cancer (MpBC) and triple-negative breast cancer (TNBC). Its lead program is a Phase 1/2 investigator-sponsored trial at Houston Methodist in combination with nab-paclitaxel and alpelisib, funded by an NIH grant.
Q2 FY2026 — expected 2026-09-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001563577-26-000005 | EDGAR | 67K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047798 | EDGAR | 77K words |
| 2024-03-28 | 2023-12-31 | 0000950170-24-037614 | EDGAR | 65K words |
| 2023-03-08 | 2022-12-31 | 0000950170-23-006588 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0000950170-22-003292 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012244 | EDGAR | — |
| 2020-03-10 | 2019-12-31 | 0001564590-20-009542 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-278816 | EDGAR | 19K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-107616 | EDGAR | 21K words |
| 2025-05-15 | 2025-03-31 | 0000950170-25-071956 | EDGAR | 20K words |
| 2024-12-13 | 2024-09-30 | 0001193125-24-277849 | EDGAR | 22K words |
| 2024-08-14 | 2024-06-30 | 0000950170-24-096654 | EDGAR | 22K words |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058197 | EDGAR | 17K words |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063361 | EDGAR | 25K words |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042058 | EDGAR | 27K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020842 | EDGAR | 21K words |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023516 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015753 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0000950170-22-009950 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0001193125-26-331207 | EDGAR | 11K words |
| 2026-07-31 | 0001193125-26-328716 | EDGAR | 1K words |
| 2026-07-13 | 0001193125-26-301997 | EDGAR | 1K words |
| 2026-04-03 | 0001193125-26-141187 | EDGAR | 1K words |
| 2026-02-18 | 0001193125-26-055919 | EDGAR | 1K words |
| 2026-02-12 | 0001193125-26-048696 | EDGAR | 1K words |
| 2025-10-27 | 0001193125-25-250698 | EDGAR | 1K words |
| 2025-10-21 | 0001193125-25-245093 | EDGAR | 1K words |
| 2025-09-03 | 0001193125-25-194948 | EDGAR | 1K words |
| 2025-04-02 | 0001193125-25-071428 | EDGAR | 1K words |
107 total filings indexed. 78 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001563577 |
| Ticker | GRTX |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GRTX (~200 tokens, structured JSON with cryptographic provenance)